Metabolism drugs are used for the treatment of obesity and weight management. These drugs are also helpful in regulating blood glucose levels, thereby assisting in the treatment of diabetes. Metabolism drugs fall under two categories namely appetite suppressants and fat/carbohydrate blockers. Appetite suppressants curb appetite by targeting various chemicals in the brain that control hunger and fullness. Whereas, fat blockers prevent the absorption of fat from the digestive tract. Diabetes and obesity have become major health concerns globally. As per World Health Organization, the number of adults living with diabetes increased from 108 million in 1980 to 422 million in 2014. The rising prevalence of obesity and diabetes is propelling the demand for effective treatment options such as metabolism drugs.

The global Metabolism Drugs Market is estimated to be valued at Us$ 9410.88 Mn in 2023 and is expected to exhibit a CAGR Of 2.3% over the forecast period 2024 To 2031, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:

The rising awareness regarding obesity management is expected to be a key driver for the global metabolism drugs market over the forecast period. Obesity is one of the leading preventable causes of death worldwide and is associated with various health risks such as cardiovascular diseases, diabetes, musculoskeletal disorders, and certain types of cancers. Therefore, people are increasingly adopting metabolism drugs to manage their weight and control obesity-related health complications. Another major driver for the market growth is increasing prevalence of diabetes globally. As per International Diabetes Federation’s Diabetes Atlas 9th edition, approximately 537 million adults were living with diabetes in 2021 worldwide. Metabolism drugs assist in regulating blood glucose levels and help manage diabetes. Hence, growing diabetes patient pool is fueling the demand for various metabolism drugs around the world.

Segment Analysis

The global metabolism drugs market can be segmented based on therapeutic area, distribution channel and geography. By therapeutic area, the market can be segmented into diabetes, inherited metabolic diseases and others. The diabetes segment is anticipated to be the largest and fastest growing segment during the forecast period. Rising prevalence of diabetes across the globe due to sedentary lifestyle and unhealthy eating habits is a major factor driving the growth of this segment.

PEST Analysis

Political: Government initiatives to spread awareness about metabolism disorders and regular screening programs are supporting market growth. Favorable regulations related to drugs approval are also encouraging pharmaceutical companies to develop new drug molecules.

Economic: Rising healthcare expenditure, increasing disposable incomes and growing geriatric population are positively impacting the market. However, high costs associated with drug development and pricing pressure limit market growth.

Social: Changing lifestyle trends, growing obese population and increasing focus on preventive healthcare are augmenting demand. Support from various advocacy groups for rare and orphan disorders also promotes adoption of metabolism drugs.

Technological: Technological advancements enable development of improved drug formulations, precision therapies and novel drug delivery mechanisms. Growing R&D activities focused on natural compound extraction also expands opportunities.

Key Takeaways

The Global Metabolism Drugs Market Size is expected to witness high growth at a CAGR of 2.3% during the forecast period of 2024-2031 driven by rising metabolic disorders prevalence worldwide. The market size is projected to reach a value of US$ 9410.88 Mn by 2024 led by aging population and associated comorbidities.

Regional analysis:

North America region held the largest share of metabolism drugs market in 2024 owing to developed healthcare infrastructure, growing awareness and presence of key players. Europe also captured significant share due to favorable reimbursement scenario. The Asia Pacific region is anticipated to showcase fastest growth over the forecast period with China and India emerging as high potential markets.

Key players:

Major players operating in the metabolism drugs market include 3M, Boehringer Ingelheim International GmbH, Novartis International AG, Eli Lilly and Company, GlaxoSmithKline plc, AstraZeneca plc. These companies are engaged in new product launches, collaborations, and geographic expansions to strengthen their market position.

Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it